Lung cancer is the leading cause of death from cancer in the United States. Better understanding of oncogenes and tumor suppressor genes involved in lung cancer hold the promise of improving clinical care of afflicted patients.
Prior work from our group has focused on transcription factors involved in lung cancer and mechanisms of sensitivity/resistance of oncogene kinases (such as EGFR, ALK, ROS1, MET, RET among others) to tyrosine kinase inhibitors in non-small-cell lung cancer.
Our group is also part of the clinical research effort at DFHCC, with a focus in non-small-cell lung cancer. We are seeking a NIH/NCI-funded SPORE in Lung Cancer at DFHCC.
(co-investigators at BIDMC: Susumu Kobayashi, MD, PhD, Daniel G. Tenen, MD; Mark Huberman, MD, Xiuning Le, MD, PhD; and Deepa Rangachari, MD)
(co-investigators at DFCI: Pasi Janne, MD, PhD; Geoffrey Oxnard, MD; David Jackman, MD; Michael Eck, MD, PhD; Matthew Meyerson, MD, PhD; and Bruce Johnson, MD)
(co-investigators at MGH: Lecia V. Sequist, MD, MPH; Justin Gainor, MD; and Alice Shaw, MD, PhD)